FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022389996> ?p ?o ?g. }

• W2022389996 endingPage "148" @default.
• W2022389996 startingPage "140" @default.
• W2022389996 abstract "Although valproate is considered to be the drug of first choice for the treatment of idiopathic generalized epilepsies (IGEs), other antiepileptic drugs (AEDs), both old (ethosuximide, clobazam, and clonazepam) and new (lamotrigine, levetiracetam, topiramate, and zonisamide) are also available. These AEDs do not appear to have a common mechanism of action in that both inhibitory gamma-aminobutyric acid (GABA; e.g., clobazam, clonazepam, and valproate) and excitatory glutamate (e.g., lamotrigine and topiramate) mechanisms are involved. Ethosuximide primarily acts by blocking T-type voltage-gated calcium channels in thalamic neurones while topiramate and zonisamide have multiple mechanisms of action. In contrast, levetiracetam is unique in that it may act via a specific binding site in the brain. In terms of their pharmacokinetic characteristics, all eight AEDs are rapidly absorbed after oral ingestion with peak blood concentration being achieved within 1-4 hours. Bioavailability is 100% with the exception clonazepam (90%) and topiramate (81-95%). Plasma protein binding is variable with valproate (90%), clobazam (85%) and clonazepam (86%) showing substantial binding, lamotrigine (55%) and zonisamide (50%) intermediate binding, and levetiracetam (0%), ethosuximide (0%) and topiramate (10%) being minimally bound. However, the binding by zonisamide is complicated by its binding to erythrocytes as well as albumin. All AEDs, with the exception of lamotrigine and levetiracetam, undergo elimination as a result of extensive metabolism by hepatic cytochrome P450 enzymes, which are highly amenable to induction and inhibition by other drugs and therefore susceptible to pharmacokinetic interactions. Lamotrigine metabolism is via hepatic glucuronidation, a process that is also susceptible to induction and inhibition by concurrent drugs. Levetiracetam is minimally metabolized (by hydrolysis in blood), is excreted predominantly unchanged in urine, and to date has not been associated with any clinically significant pharmacokinetic interactions. Using a semiquantitative pharmacokinetic rating system, based on 16 pharmacokinetic characteristics, a direct comparison between AEDs is possible. Thus valproic acid, regarded as the drug of first choice in the treatment of IGEs, rates lowest with respect to favorable pharmacokinetic characteristics, mostly because of its nonlinear pharmacokinetics, extensive hepatic metabolism, and its high propensity to interact both with other AEDs and non-AEDs. Levetiracetam rates highest with topiramate in second place." @default.
• W2022389996 created "2016-06-24" @default.
• W2022389996 creator A5083062583 @default.
• W2022389996 date "2005-11-01" @default.
• W2022389996 modified "2023-10-14" @default.
• W2022389996 title "Properties of Antiepileptic Drugs in the Treatment of Idiopathic Generalized Epilepsies" @default.
• W2022389996 cites W103743773 @default.
• W2022389996 cites W105915516 @default.
• W2022389996 cites W1972895093 @default.
• W2022389996 cites W1975223621 @default.
• W2022389996 cites W1976010985 @default.
• W2022389996 cites W1977132977 @default.
• W2022389996 cites W1978301229 @default.
• W2022389996 cites W1983073359 @default.
• W2022389996 cites W1990832688 @default.
• W2022389996 cites W1990903458 @default.
• W2022389996 cites W1996896888 @default.
• W2022389996 cites W2004955749 @default.
• W2022389996 cites W2010356902 @default.
• W2022389996 cites W2017898520 @default.
• W2022389996 cites W2022778609 @default.
• W2022389996 cites W2023684600 @default.
• W2022389996 cites W2024035693 @default.
• W2022389996 cites W2025734764 @default.
• W2022389996 cites W2026506987 @default.
• W2022389996 cites W2033614870 @default.
• W2022389996 cites W2037292769 @default.
• W2022389996 cites W2039100312 @default.
• W2022389996 cites W2040710422 @default.
• W2022389996 cites W2041295849 @default.
• W2022389996 cites W2041682276 @default.
• W2022389996 cites W2043818223 @default.
• W2022389996 cites W2047355574 @default.
• W2022389996 cites W2051368800 @default.
• W2022389996 cites W2067075698 @default.
• W2022389996 cites W2069883703 @default.
• W2022389996 cites W2070828451 @default.
• W2022389996 cites W2078387400 @default.
• W2022389996 cites W2083623577 @default.
• W2022389996 cites W2092256984 @default.
• W2022389996 cites W2092605585 @default.
• W2022389996 cites W2094796128 @default.
• W2022389996 cites W2099210136 @default.
• W2022389996 cites W2124810389 @default.
• W2022389996 cites W2127801604 @default.
• W2022389996 cites W2134200996 @default.
• W2022389996 cites W2166513726 @default.
• W2022389996 cites W2187230393 @default.
• W2022389996 doi "https://doi.org/10.1111/j.1528-1167.2005.00326.x" @default.
• W2022389996 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16302888" @default.
• W2022389996 hasPublicationYear "2005" @default.
• W2022389996 type Work @default.
• W2022389996 sameAs 2022389996 @default.
• W2022389996 citedByCount "105" @default.
• W2022389996 countsByYear W20223899962012 @default.
• W2022389996 countsByYear W20223899962013 @default.
• W2022389996 countsByYear W20223899962014 @default.
• W2022389996 countsByYear W20223899962015 @default.
• W2022389996 countsByYear W20223899962016 @default.
• W2022389996 countsByYear W20223899962017 @default.
• W2022389996 countsByYear W20223899962018 @default.
• W2022389996 countsByYear W20223899962019 @default.
• W2022389996 countsByYear W20223899962020 @default.
• W2022389996 countsByYear W20223899962021 @default.
• W2022389996 countsByYear W20223899962022 @default.
• W2022389996 countsByYear W20223899962023 @default.
• W2022389996 crossrefType "journal-article" @default.
• W2022389996 hasAuthorship W2022389996A5083062583 @default.
• W2022389996 hasBestOaLocation W20223899961 @default.
• W2022389996 hasConcept C112705442 @default.
• W2022389996 hasConcept C118552586 @default.
• W2022389996 hasConcept C185592680 @default.
• W2022389996 hasConcept C2775858608 @default.
• W2022389996 hasConcept C2777138316 @default.
• W2022389996 hasConcept C2777332695 @default.
• W2022389996 hasConcept C2777683783 @default.
• W2022389996 hasConcept C2777907850 @default.
• W2022389996 hasConcept C2778186239 @default.
• W2022389996 hasConcept C2778802184 @default.
• W2022389996 hasConcept C2779253243 @default.
• W2022389996 hasConcept C2779426884 @default.
• W2022389996 hasConcept C2779619453 @default.
• W2022389996 hasConcept C2781176495 @default.
• W2022389996 hasConcept C71924100 @default.
• W2022389996 hasConcept C98274493 @default.
• W2022389996 hasConceptScore W2022389996C112705442 @default.
• W2022389996 hasConceptScore W2022389996C118552586 @default.
• W2022389996 hasConceptScore W2022389996C185592680 @default.
• W2022389996 hasConceptScore W2022389996C2775858608 @default.
• W2022389996 hasConceptScore W2022389996C2777138316 @default.
• W2022389996 hasConceptScore W2022389996C2777332695 @default.
• W2022389996 hasConceptScore W2022389996C2777683783 @default.
• W2022389996 hasConceptScore W2022389996C2777907850 @default.
• W2022389996 hasConceptScore W2022389996C2778186239 @default.
• W2022389996 hasConceptScore W2022389996C2778802184 @default.
• W2022389996 hasConceptScore W2022389996C2779253243 @default.
• W2022389996 hasConceptScore W2022389996C2779426884 @default.
• W2022389996 hasConceptScore W2022389996C2779619453 @default.

• next